Skip to main content
VERA
NASDAQ Life Sciences

Vera Therapeutics Reports Strong Financial Position and Advances Lead Drug Atacicept Towards FDA Approval

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$42.12
Mkt Cap
$2.967B
52W Low
$18.53
52W High
$56.05
52W Position info
127% above low
Off High info
25% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

VERA has more than doubled off its 52-week low of $18.53.

Summary

Vera Therapeutics' 2025 annual report details significant progress for its lead drug atacicept, including FDA Priority Review, supported by a strong financial position from recent capital raises despite increased R&D expenses.


Key Events · Product Development and Regulatory · VERA

  • FDA Priority Review for Atacicept

    The FDA granted Priority Review for atacicept's Biologics License Application (BLA) for IgAN, setting a PDUFA target action date of July 7, 2026. This follows the successful meeting of the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial in June 2025.

  • Strong Liquidity Position

    As of December 31, 2025, the company held $714.6 million in cash, cash equivalents, and marketable securities, up from $640.9 million in 2024. Management anticipates this capital will fund operations for at least the next 12 months.

  • Successful Capital Raises

    Vera Therapeutics completed follow-on public offerings in 2024 and 2025, raising aggregate net proceeds of approximately $874.5 million. Additionally, a new $500 million debt facility was established in June 2025, with $75 million funded.

  • Increased R&D and G&A Expenses

    Net loss for 2025 increased to $299.6 million from $152.1 million in 2024, driven by a 71% increase in R&D expenses to $215.3 million and a 144% increase in general and administrative expenses to $100.2 million, reflecting advanced clinical trials and commercialization planning.


Analysis · VERA · Life Sciences

Vera Therapeutics' annual report highlights significant progress for its lead product candidate, atacicept, which received FDA Priority Review for its Biologics License Application (BLA) for IgAN with a PDUFA target action date of July 7, 2026. This regulatory advancement, following positive Phase 3 trial results, is a critical step towards potential commercialization. Financially, the company reported a net loss of $299.6 million for 2025, an increase from the prior year, reflecting intensified research and development and commercialization preparation efforts. However, the company significantly bolstered its liquidity through successful follow-on public offerings in 2024 and 2025, raising over $870 million, and a new $500 million debt facility. With $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, management projects sufficient funding for at least the next 12 months, providing a solid runway for its pipeline development and commercial launch preparations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERA was trading at $42.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $18.53 to $56.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERA - Latest Insights

VERA
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $29.53
Real-time Price: $25.26 info
Change: -$4.27 (-14%) info
Market Cap: $1.823B info
VERA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.07
Real-time Price: $25.26 info
Change: -$5.81 (-19%) info
Market Cap: $1.823B info
VERA
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $25.26 info
Change: -$5.72 (-18%) info
Market Cap: $1.823B info
VERA
Sep 15, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.64
Real-time Price: $25.26 info
Change: -$13.38 (-35%) info
Market Cap: $1.823B info
VERA
Sep 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.69
Real-time Price: $25.26 info
Change: -$12.43 (-33%) info
Market Cap: $1.823B info